Alterations of Gut Microbiota in Cholestatic Infants and Their Correlation With Hepatic FunctionOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
This study characterized the gut microbiome in infants with cholestasis, a liver condition of impaired bile flow, and asked how it relates to hepatic function. It compared cholestatic and healthy infants. Stool bacteria were profiled by 16S rRNA sequencing of the V3-V4 region on an Illumina MiSeq. The team measured diversity, differential genera, co-occurrence networks, PICRUSt-predicted functions, and correlations with eight liver blood markers, and built a Random Forest biomarker classifier.
Who was studied?
The study enrolled 43 cholestatic infants and 37 healthy infants at three hospitals in Hebei, China, between December 2016 and January 2018. All were under three years old. Cholestatic infants averaged about 2 months of age and healthy infants about 12 months, and the groups also differed in delivery and feeding pattern. Among the patients, 9 had biliary atresia and 5 had cytomegalovirus hepatitis, with the rest of no discernible cause. Infants on recent antibiotics or probiotics were excluded.
What were the most important findings?
Cholestatic infants had significantly lower bacterial diversity than healthy infants, with a mean Shannon index of 2.222 versus 2.669 (p = 0.013). PERMANOVA linked between-group differences mainly to feeding pattern. Thirteen of the top genera were differentially abundant, and the patient co-occurrence network was more complex with three core nodes. A 28-genus Random Forest biomarker set distinguished patients from healthy infants with AUC above 0.97. Predicted lipid and xenobiotic metabolism rose while amino acid, nucleotide, and vitamin metabolism fell.
What are the greatest implications of this study?
Infantile cholestasis is marked by a distinct, lower-diversity gut community that tracks with liver function markers such as bilirubin and GGT. This supports a gut-liver axis role in the disease. The high-accuracy bacterial biomarker set points toward a possible non-invasive way to flag cholestasis, and suggests microbiome-directed intervention as a research direction. The authors caution that the cohort was modest and single-region, so biomarkers need validation in larger, ethnically varied populations before clinical use.